The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...

Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin ...

To keep your blood sugar in a safe range, you may take long-acting insulin, short-acting insulin, or both. Doctors usually recommend trying long-acting insulin first. Long-acting (basal ...

Sliding scale insulin therapy involves following a chart of insulin dosages. A doctor will help a person with diabetes create this chart based on factors like how their body responds to insulin ...

The rapid-acting insulin aspart biosimilar joins two prior long-acting insulin biosimilar products approved in 2021. Biosimilars are highly similar to already approved products and have no ...

Crucially, the long-acting insulin was no worse than Tresiba when it came to rates of hypoglycaemia, when blood glucose levels dip too low, according to statistical comparisons between the drugs.

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin ...

The FDA noted that Merilog is the third insulin biosimilar product to get its approval. In 2021, the agency had approved two long-acting insulin biosimilar products. A biosimilar is a biological ...

Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved in 2021 by the FDA. Approval of biosimilar products can ...

SILVER SPRING, Md., Feb. 14, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement ...